αB‐crystallin is a useful marker for triple negative and basal breast cancers

Tsang, Julia Y. S.; Lai, Michael W H; Wong, Ken; Chan, Siu‐Ki; Lam, Christopher; Tsang, Alex K H; Yu, Alex M C; Tan, Puay‐Hoon; Tse, Gary M.

doi:10.1111/j.1365-2559.2012.04234.x

Cited by 30 publications

(25 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunohistochemical expression of ABC was found in 41% of 29 cases of MBC, mainly within the epithelial component as well as in the spindle cell or sarcomatous component in five cases,69 compared with 56% of BLBC, and no ER positive or HER2 positive carcinomas, a finding which has been replicated in some,72 but not other studies70 (the latter including only five cases of MBC).…”

Section: Molecular Features Of Mbcmentioning

confidence: 67%

“…It inhibits apoptosis, suppressing the autocatalytic maturation of caspase-367 and preventing the mitochondrial translocation of the pro-apoptotic Bcl-2 proteins Bax and Bcl-x s 68. It also has a cytoprotective effect, functioning as a molecular chaperone to inhibit intracellular aggregation of denatured proteins69 and can be induced by stressors including chemotherapy, reactive oxygen species and heat shock 70. ABC overexpression in xenograft models is tumourigeneic, inducing both mesenchymal-like spindle elements and atypical glandular elements with invasive properties, which may indicate a role in EMT 71…”

Section: Molecular Features Of Mbcmentioning

confidence: 99%

See 1 more Smart Citation

Molecular alterations in metaplastic breast carcinoma

et al. 2013

View full text Add to dashboard Cite

Metaplastic carcinoma of the breast is a rare and heterogeneous subtype of breast carcinoma with a generally poor outcome, and few therapeutic options once disease recurs or progresses. Metaplastic carcinomas of the breast are usually of a larger size at diagnosis, with less frequent nodal metastasis compared with invasive ductal carcinoma no special type, and lack hormone and HER2 receptor expression. Recent research has revealed some potentially actionable genetic changes in a subset of these rare tumours. However, ongoing efforts to further characterise the genetic basis and the molecular alterations underlying the distinctive morphological and clinical characteristics of these tumours are needed in order to identify new targets for treatment. This review will describe the theories of pathogenesis of metaplastic breast carcinoma, and highlight genetic changes and potential therapeutic targets in this generally poor prognosis malignancy.

show abstract

Section: Molecular Features Of Mbcmentioning

confidence: 67%

Section: Molecular Features Of Mbcmentioning

confidence: 99%

Molecular alterations in metaplastic breast carcinoma

et al. 2013

View full text Add to dashboard Cite

show abstract

“…TMAs containing representative areas of breast cancer cases were constructed with duplicated 1.5 μm tissue cores as previously described 24. One section from each TMA was stained with H&E and reviewed to confirm the presence of representative tumours.…”

Section: Methodsmentioning

confidence: 99%

Nerve growth factor receptor (NGFR): a potential marker for specific molecular subtypes of breast cancer

et al. 2012

Self Cite

View full text Add to dashboard Cite

show abstract

“…51 In a recent study of ab-crystallin, the sensitivity (56.5%) and specificity (92.9%) for BLBC was found to be higher than those of other basal markers such as CK5/6 and EGFR. 52 These findings suggest that ab-crystallin can serve as a new marker for BLBC and a potential target for therapy.…”

Section: Proliferation-related Proteinsmentioning

confidence: 99%

Basal-Like Breast Cancer: Update on Clinicopathologic, Immunohistochemical, and Molecular Features

Leidy

Khan

Kandil

2014

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.-Basal-like breast carcinoma (BLBC) is a distinct molecular subtype of breast carcinoma identified through gene expression profiling studies.Objective.-To provide the clinical background, the histologic profile, and the immunohistochemical profile of these tumors and discuss the current knowledge of their molecular signature and their implications on targeted molecular therapy.Data Sources.-Data were obtained from review of the pertinent peer-reviewed literature.Conclusions.-Basal-like breast carcinomas are aggressive tumors with poor prognosis. Lack of targeted therapy makes their treatment a challenging task. Traditional chemotherapy is still associated with a high risk of relapse and death in a high percentage of patients. Platinum-based chemotherapy has been considered as a candidate for the treatment of BLBCs owing to their BRCA1 phenotype. Approximately 22% of patients treated with single-agent cisplatin show pathologic complete response, which is a comparable rate to that seen with nonplatinum agents. Antiangiogenic agents have been promising, but their currently demonstrated limited response is considered disappointing. Additionally, epidermal growth factor receptor was not shown to be a helpful target for BLBC. A recent study has shown that BLBC appears to be especially sensitive to MEK inhibitors, making it a promising therapeutic possibility. The list of new targets is still evolving and the ''magic'' therapeutic target is yet to be discovered.

show abstract

αB‐crystallin is a useful marker for triple negative and basal breast cancers

Abstract: The findings indicated that αB-crystallin was a highly sensitive and specific marker for TNBCs and BLBCs.

Cited by 30 publications

References 23 publications

Molecular alterations in metaplastic breast carcinoma

Molecular alterations in metaplastic breast carcinoma

Nerve growth factor receptor (NGFR): a potential marker for specific molecular subtypes of breast cancer

Basal-Like Breast Cancer: Update on Clinicopathologic, Immunohistochemical, and Molecular Features

Contact Info

Product

Resources

About